Canada Markets open in 7 hrs 2 mins

Deciphera Pharmaceuticals, Inc. (DCPH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.50+0.88 (+4.99%)
At close: 04:00PM EDT
18.02 -0.48 (-2.59%)
After hours: 07:33PM EDT

Deciphera Pharmaceuticals, Inc.

200 Smith Street
Waltham, MA 02451
United States
781 209 6400
https://www.deciphera.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees280

Key Executives

NameTitlePayExercisedYear Born
Mr. Steven L. HoerterPres, CEO & Director1.01M23.54k1971
Dr. Daniel L. Flynn Ph.D.Exec. VP, Chief Scientific Officer & Founder645.61kN/A1955
Mr. Thomas Patrick Kelly J.D.Exec. VP, CFO & Treasurer644.12kN/A1971
Mr. Daniel C. MartinSr. VP & Chief Commercial Officer611.24kN/A1975
Dr. Matthew L. Sherman M.D.Exec. VP & Chief Medical Officer725.85kN/A1956
Dr. Stephen B. Ruddy Ph.D.Sr. VP & Chief Technical OfficerN/AN/A1964
Ms. Jennifer RobinsonVP of Investor RelationsN/AN/AN/A
Mr. Jeffrey M. Held J.D.Sr. VP & Gen. CounselN/AN/AN/A
Ms. Jama PitmanSr. VP of Regulatory, Quality & Portfolio ManagementN/AN/A1979
Ms. Margarida DuarteSr. VP & Head of InternationalN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Deciphera Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2022 is 10. The pillar scores are Audit: 7; Board: 8; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.